---
title: "Twelve People Got the Implant. Insurance Now Pays a Third of the Bill."
date: 2026-11-13
category: Brain–Computer Interface
site: NeuroAI
canonical: https://neuroai.site/a/na-brain-neo-huibao-reimbursement
language: en
---

# Twelve People Got the Implant. Insurance Now Pays a Third of the Bill.

> Daily AI industry briefing from Brain-Computer Network: verified facts, sourced numbers.

A brain-computer interface product has gained something it never had before: a reimbursement line.

According to Xinmin Evening News, organizers disclosed at a November 12 press briefing for the 2026 Brain-Computer Interface Conference that the NEO system developed by BrightRock has completed 12 commercial implants to date, with treatment costs now covered by Shanghai's Huibao supplementary medical insurance at a reimbursement rate of up to 30 percent.

## From First License to First Prescription

NEO is an implantable system that compensates for lost hand movement, using minimally invasive implantation outside the dura mater and wireless power and communication. It received its Class III medical device registration from China's drug regulator on March 13, officially described as the world's first approved invasive brain-computer interface product.

Commercialization followed within four months. On July 13, Huashan Hospital in Shanghai issued the product's first clinical prescription and completed the first commercial implant the same day.

The clinical case rests on numbers disclosed at the briefing: among 32 tetraplegic patients followed for 12 months after surgery, 81.3 percent achieved neurological function recovery, hand-grasp improvement met clinical significance thresholds, and cumulative safe home use has surpassed 19,000 days.

## One Hundred Twenty-One Patients

The industry figure offered at the briefing: 121 patients nationwide have benefited from brain-interface technology. Behind that number, three technical routes are advancing in parallel.

On the epidural semi-invasive route, Beijing Xinzhide's "Brain One" system has completed more than 40 human implants, with the longest patient exceeding 18 months and cumulative safe operation above 170,000 hours; registration trial enrollment is complete and a Class III application is planned for 2027.

On the subdural route, NeuroXess launched a GCP registration trial at Huashan Hospital in July, run jointly with nearly 20 tertiary hospitals across the country.

Zhiran Medical started China's first multi-center GCP trial of a system with more than a hundred channels in May, led by Beijing Tiantan Hospital, planning to enroll 32 spinal-cord injury patients with completion expected in 2027.

## What Insurance Still Needs

Hong Bo, chief scientist at the Lingang Laboratory, was explicit at the briefing: implanted brain interfaces are high-risk Class III active medical devices, the regulatory bar is extremely high, and long-term safety validation with large follow-up cohorts is unavoidable.

His reference points: 40 to 50 hospitals nationwide have opened brain-interface wards, 20 of them capable of invasive surgery, but national basic medical insurance coverage will require more cases and two to three years of data.

Supplementary insurance products such as Huibao are stepping into that gap first, letting patients recover part of the cost while the evidence accumulates. The design is deliberate: a city-level pool spreads the risk of an expensive new therapy across millions of small premiums, and every reimbursed case generates the follow-up data that national insurance reviewers will eventually demand. Twelve reimbursed implants is a small number against a national patient population, but it converts a laboratory therapy into a line item on an insurance schedule, which is where medical technologies stop being experiments.

Hong also drew the boundary of the current market clearly. The commercially available implants today serve patients with high-level paralysis from trauma; stroke, Parkinson's, depression, epilepsy and dementia products remain in research and trials. The consumer brain-interface wave that headlines promise is still behind a clinical wall, and the wall's gatekeeper is accumulated patient data.

From first license to first prescription to first reimbursement, brain interfaces walked the first three steps of commercialization in 2026. The road ahead depends on more surgeries and longer follow-up data.

**Disclaimer: This article is based on public information and is for reference only. It does not constitute any investment advice.**

---

Published by NeuroAI (https://neuroai.site/) — https://neuroai.site/a/na-brain-neo-huibao-reimbursement
Free to quote with attribution and a link to the original.
